Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
MGC Pharmaceuticals Ltd - Perth, Australia-based medicinal cannabis company - Says ‘strong’ quarterly sales continue, notes A$1.6 million, about £923,000, in cash receipts during three month period to June 30. In 12-month period, records A$6.1 million in cash receipts.
‘Cost reduction strategy implemented in June quarter including reduction in material R&D costs, with future non-core trials also deferred,’ company says.
Co-founder and Managing Director Roby Zomer adds: ‘Getting pharmaceutical products through the regulatory approval process takes time, particularly when the products are phytocannabinoids. I am, however, confident in the team and the strategy that has been developed to help ensure this process and that MGC Pharma's products will be able to make a difference to patients suffering with debilitating conditions.’
Current stock price: 1.24 pence, up 3.7% on Monday
12-month change: down 43%
Copyright 2022 Alliance News Limited. All Rights Reserved.